Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Heres

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Social Psychiatry and Psychiatric Epidemiology|April 16, 2021
Employment status and desire for work in severe mental illness: results from an observational, cross-sectional studyUta Gühne, Alexander Pabst, Margrit Löbner, et al.
BMC Psychiatry|February 16, 2022
The role of migration in mental healthcare: treatment satisfaction and utilizationGabriele Gaigl, Esther Täumer, Andreas Allgöwer, et al.
Community Mental Health Journal|July 1, 2026
Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional StudySimon Noah Stein, Sophia Kraake, Alexander Pabst, et al.
The Lancet. Psychiatry|August 18, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching studyRené S Kahn, Inge Winter van Rossum, Stefan Leucht, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 6, 2019
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and designChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
BMC Medicine|July 29, 2024
The impact of a digital guideline version on schizophrenia guideline knowledge: results from a multicenter cluster-randomized controlled trialTheresa Halms, Gabriele Gaigl, Carolin Lorenz, et al.
Schizophrenia Bulletin|July 20, 2022
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With SchizophreniaStephan Heres, Joachim Cordes, Sandra Feyerabend, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Social Psychiatry and Psychiatric Epidemiology|April 16, 2021
Employment status and desire for work in severe mental illness: results from an observational, cross-sectional studyUta Gühne, Alexander Pabst, Margrit Löbner, et al.
BMC Psychiatry|February 16, 2022
The role of migration in mental healthcare: treatment satisfaction and utilizationGabriele Gaigl, Esther Täumer, Andreas Allgöwer, et al.
Community Mental Health Journal|July 1, 2026
Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional StudySimon Noah Stein, Sophia Kraake, Alexander Pabst, et al.
The Lancet. Psychiatry|August 18, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching studyRené S Kahn, Inge Winter van Rossum, Stefan Leucht, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 6, 2019
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and designChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
BMC Medicine|July 29, 2024
The impact of a digital guideline version on schizophrenia guideline knowledge: results from a multicenter cluster-randomized controlled trialTheresa Halms, Gabriele Gaigl, Carolin Lorenz, et al.
Schizophrenia Bulletin|July 20, 2022
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With SchizophreniaStephan Heres, Joachim Cordes, Sandra Feyerabend, et al.
Pageof 9